Trulieve Cannabis (NYSE:TRLV – Get Free Report) and IM Cannabis (NASDAQ:IMCC – Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.
Analyst Ratings
This is a breakdown of current recommendations for Trulieve Cannabis and IM Cannabis, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Trulieve Cannabis | 1 | 1 | 1 | 0 | 2.00 |
| IM Cannabis | 1 | 0 | 0 | 0 | 1.00 |
Trulieve Cannabis presently has a consensus price target of $15.00, indicating a potential upside of 46.34%. Given Trulieve Cannabis’ stronger consensus rating and higher probable upside, research analysts clearly believe Trulieve Cannabis is more favorable than IM Cannabis.
Institutional and Insider Ownership
7.7% of IM Cannabis shares are held by institutional investors. 3.8% of Trulieve Cannabis shares are held by company insiders. Comparatively, 5.9% of IM Cannabis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Profitability
This table compares Trulieve Cannabis and IM Cannabis’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Trulieve Cannabis | -41.55% | -4.24% | -1.72% |
| IM Cannabis | -39.62% | N/A | -58.32% |
Valuation & Earnings
This table compares Trulieve Cannabis and IM Cannabis”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Trulieve Cannabis | $1.18 billion | 1.67 | -$116.38 million | $0.11 | 93.18 |
| IM Cannabis | $39.17 million | 0.02 | -$8.10 million | ($60.66) | -0.01 |
IM Cannabis has lower revenue, but higher earnings than Trulieve Cannabis. IM Cannabis is trading at a lower price-to-earnings ratio than Trulieve Cannabis, indicating that it is currently the more affordable of the two stocks.
Summary
Trulieve Cannabis beats IM Cannabis on 8 of the 13 factors compared between the two stocks.
About Trulieve Cannabis
Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company. The company cultivates and produces products in-house and distributes its products to Trulieve branded stores (dispensaries) in Florida, California, Massachusetts, Connecticut, Pennsylvania, and West Virginia, as well as directly to patients through home delivery. It produces approximately 550 stock keeping units, including flower, edibles, vaporizer cartridges, concentrates, topicals, capsules, tinctures, dissolvable powders, and nasal sprays. As of May 5, 2021, the company operated through 87 dispensaries in the United States. The company is headquartered in Quincy, Florida.
About IM Cannabis
IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.
Receive News & Ratings for Trulieve Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trulieve Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.
